Omeros reported a net loss of $7.5 million, or $0.16 per share, for the third quarter of 2017 compared with a net loss of $14 million, or $0.34 per share, in the same period of 2016.
Revenues from Omidria (phenylephrine 1% and ketorolac 0.3% injection) rose from $11.3 million in 2016’s third quarter to $21.7 million in 2017’s third quarter, according to a press release.
Total costs and expenses increased from $23.3 million to $26.8 million, which Omeros attributed to increased third-party manufacturing costs for OMS721, higher costs for advancing (Read more...)
Uncategorized